A prognostic score for patients with intermediate-stage hepatocellular carcinoma treated with transarterial chemoembolization
Intermediate-stage hepatocellular carcinoma (HCC), defined according to the Barcelona Clinic Liver Cancer (BCLC) staging system, is a heterogeneous condition with variable clinical benefits from transarterial chemoembolization (TACE). This study aimed to develop a simple validated prognostic score b...
Gespeichert in:
| Veröffentlicht in: | PloS one 2015-04, Vol.10 (4), p.e0125244-e0125244 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0125244 |
|---|---|
| container_issue | 4 |
| container_start_page | e0125244 |
| container_title | PloS one |
| container_volume | 10 |
| creator | Ogasawara, Sadahisa Chiba, Tetsuhiro Ooka, Yoshihiko Kanogawa, Naoya Motoyama, Tenyu Suzuki, Eiichiro Tawada, Akinobu Azemoto, Ryosaku Shinozaki, Masami Yoshikawa, Masaharu Yokosuka, Osamu |
| description | Intermediate-stage hepatocellular carcinoma (HCC), defined according to the Barcelona Clinic Liver Cancer (BCLC) staging system, is a heterogeneous condition with variable clinical benefits from transarterial chemoembolization (TACE). This study aimed to develop a simple validated prognostic score based on the predictive factors for survival in patients with intermediate-stage HCC treated with TACE.
Three-hundred and fifty patients with intermediate-stage HCC undergoing initial TACE at Chiba University Hospital (training cohort; n = 187) and two affiliated hospitals (validation cohort; n = 163) were included. Following variables were entered into univariate and multivariate Cox regression models to develop a points-based clinical scoring system: gender, age, etiology, pretreatment, Child-Pugh score, aspartate aminotransferase, creatinine, C-reactive protein, alfa-fetoprotein, size of the largest lesion, and number and location of lesions.
The number of lesions and the Child-Pugh score were identified as independent prognostic factors in the training cohort. The development of a 0-7-point prognostic score, named the Chiba HCC in intermediate-stage prognostic (CHIP) score, was based on the sum of three subscale scores (Child-Pugh score = 0, 1, 2, or 3, respectively, number of lesions = 0, 2, or 3, respectively, HCV-RNA positivity = 0 or 1, respectively). The generated scores were then differentiated into five groups (0-2 points, 3 points, 4 points, 5 points, and 6-7 points) by the median survival time (65.2, 29.2, 24.3, 13.1, and 8.4 months, respectively; p < 0.0001). These results were confirmed in the external validation cohort (p < 0.0001).
The CHIP score is easy-to-use and may assist in finding an appropriate treatment strategy for intermediate-stage HCC. |
| doi_str_mv | 10.1371/journal.pone.0125244 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1676336709</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A421488671</galeid><doaj_id>oai_doaj_org_article_b1de3ce51bf44d598846cdeb56032075</doaj_id><sourcerecordid>A421488671</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-b515516c6a81867461df044feb7822af46bdce2ad9c556d9b63452a0c0ae72ac3</originalsourceid><addsrcrecordid>eNqNk12L1DAUhoso7rr6D0QLgujFjEmapO2NMCx-DCws-HUbTtPTNkPbzCapX-B_N92ZXWZkLyQXDenzvsl5k5MkTylZ0iynbzZ2ciP0y60dcUkoE4zze8kpLTO2kIxk9w_mJ8kj7zeEiKyQ8mFywkRJS8LEafJnlW6dbUfrg9Gp19Zh2liXbiEYHINPf5jQpWYM6AasDQRc-AAtph1GxGrs-6kHl2pw2ox2gDQ4jFS9EwYHowcX1Qb6VHc4WBwq25vf0d-Oj5MHDfQen-y_Z8nX9---nH9cXFx-WJ-vLhZaliwsKkGFoFJLKGghcy5p3RDOG6zygjFouKxqjQzqUgsh67KSGRcMiCaAOQOdnSXPd77b3nq1T84rKnOZZTInZSTWO6K2sFFbZwZwv5QFo64XrGtVLMPoHlVFa8w0Clo1nNeiLAoudY2VkCRjJBfR6-1-t6mKoemYo4P-yPT4z2g61drvivN4jfl8mFd7A2evJvRBDcbPUcOIdro-d16UPGYT0Rf_oHdXt6daiAWYsbFxXz2bqhVnlBcxVRqp5R1UHDUORsdn1pi4fiR4fSSITMCfoYXJe7X-_On_2ctvx-zLA7ZD6EPnbT_NT8Yfg3wHame9d9jchkyJmrvkJg01d4nad0mUPTu8oFvRTVtkfwFmLw_z</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1676336709</pqid></control><display><type>article</type><title>A prognostic score for patients with intermediate-stage hepatocellular carcinoma treated with transarterial chemoembolization</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Public Library of Science (PLoS)</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Ogasawara, Sadahisa ; Chiba, Tetsuhiro ; Ooka, Yoshihiko ; Kanogawa, Naoya ; Motoyama, Tenyu ; Suzuki, Eiichiro ; Tawada, Akinobu ; Azemoto, Ryosaku ; Shinozaki, Masami ; Yoshikawa, Masaharu ; Yokosuka, Osamu</creator><contributor>Huang, Yi-Hsiang</contributor><creatorcontrib>Ogasawara, Sadahisa ; Chiba, Tetsuhiro ; Ooka, Yoshihiko ; Kanogawa, Naoya ; Motoyama, Tenyu ; Suzuki, Eiichiro ; Tawada, Akinobu ; Azemoto, Ryosaku ; Shinozaki, Masami ; Yoshikawa, Masaharu ; Yokosuka, Osamu ; Huang, Yi-Hsiang</creatorcontrib><description>Intermediate-stage hepatocellular carcinoma (HCC), defined according to the Barcelona Clinic Liver Cancer (BCLC) staging system, is a heterogeneous condition with variable clinical benefits from transarterial chemoembolization (TACE). This study aimed to develop a simple validated prognostic score based on the predictive factors for survival in patients with intermediate-stage HCC treated with TACE.
Three-hundred and fifty patients with intermediate-stage HCC undergoing initial TACE at Chiba University Hospital (training cohort; n = 187) and two affiliated hospitals (validation cohort; n = 163) were included. Following variables were entered into univariate and multivariate Cox regression models to develop a points-based clinical scoring system: gender, age, etiology, pretreatment, Child-Pugh score, aspartate aminotransferase, creatinine, C-reactive protein, alfa-fetoprotein, size of the largest lesion, and number and location of lesions.
The number of lesions and the Child-Pugh score were identified as independent prognostic factors in the training cohort. The development of a 0-7-point prognostic score, named the Chiba HCC in intermediate-stage prognostic (CHIP) score, was based on the sum of three subscale scores (Child-Pugh score = 0, 1, 2, or 3, respectively, number of lesions = 0, 2, or 3, respectively, HCV-RNA positivity = 0 or 1, respectively). The generated scores were then differentiated into five groups (0-2 points, 3 points, 4 points, 5 points, and 6-7 points) by the median survival time (65.2, 29.2, 24.3, 13.1, and 8.4 months, respectively; p < 0.0001). These results were confirmed in the external validation cohort (p < 0.0001).
The CHIP score is easy-to-use and may assist in finding an appropriate treatment strategy for intermediate-stage HCC.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0125244</identifier><identifier>PMID: 25919025</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Aged ; Aspartate ; Aspartate aminotransferase ; C-reactive protein ; Carcinoma, Hepatocellular - blood supply ; Carcinoma, Hepatocellular - mortality ; Carcinoma, Hepatocellular - pathology ; Carcinoma, Hepatocellular - therapy ; Care and treatment ; Chemoembolization ; Chemoembolization, Therapeutic ; Creatinine ; Datasets ; Development and progression ; Etiology ; Female ; Gastroenterology ; Hepatitis C virus ; Hepatocellular carcinoma ; Hospitals ; Humans ; Kaplan-Meier Estimate ; Lesions ; Liver ; Liver cancer ; Liver Neoplasms - blood supply ; Liver Neoplasms - mortality ; Liver Neoplasms - pathology ; Liver Neoplasms - therapy ; Male ; Medical prognosis ; Medicine ; Multivariate Analysis ; Neoplasm Staging ; Nephrology ; Patients ; Pretreatment ; Prognosis ; Proteins ; Regression analysis ; Regression models ; Reproducibility of Results ; Ribonucleic acid ; RNA ; Statistical analysis ; Survival ; Survival analysis ; Tomography ; Training ; Tumors</subject><ispartof>PloS one, 2015-04, Vol.10 (4), p.e0125244-e0125244</ispartof><rights>COPYRIGHT 2015 Public Library of Science</rights><rights>2015 Ogasawara et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2015 Ogasawara et al 2015 Ogasawara et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-b515516c6a81867461df044feb7822af46bdce2ad9c556d9b63452a0c0ae72ac3</citedby><cites>FETCH-LOGICAL-c692t-b515516c6a81867461df044feb7822af46bdce2ad9c556d9b63452a0c0ae72ac3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412579/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412579/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2095,2914,23846,27903,27904,53770,53772,79347,79348</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25919025$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Huang, Yi-Hsiang</contributor><creatorcontrib>Ogasawara, Sadahisa</creatorcontrib><creatorcontrib>Chiba, Tetsuhiro</creatorcontrib><creatorcontrib>Ooka, Yoshihiko</creatorcontrib><creatorcontrib>Kanogawa, Naoya</creatorcontrib><creatorcontrib>Motoyama, Tenyu</creatorcontrib><creatorcontrib>Suzuki, Eiichiro</creatorcontrib><creatorcontrib>Tawada, Akinobu</creatorcontrib><creatorcontrib>Azemoto, Ryosaku</creatorcontrib><creatorcontrib>Shinozaki, Masami</creatorcontrib><creatorcontrib>Yoshikawa, Masaharu</creatorcontrib><creatorcontrib>Yokosuka, Osamu</creatorcontrib><title>A prognostic score for patients with intermediate-stage hepatocellular carcinoma treated with transarterial chemoembolization</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Intermediate-stage hepatocellular carcinoma (HCC), defined according to the Barcelona Clinic Liver Cancer (BCLC) staging system, is a heterogeneous condition with variable clinical benefits from transarterial chemoembolization (TACE). This study aimed to develop a simple validated prognostic score based on the predictive factors for survival in patients with intermediate-stage HCC treated with TACE.
Three-hundred and fifty patients with intermediate-stage HCC undergoing initial TACE at Chiba University Hospital (training cohort; n = 187) and two affiliated hospitals (validation cohort; n = 163) were included. Following variables were entered into univariate and multivariate Cox regression models to develop a points-based clinical scoring system: gender, age, etiology, pretreatment, Child-Pugh score, aspartate aminotransferase, creatinine, C-reactive protein, alfa-fetoprotein, size of the largest lesion, and number and location of lesions.
The number of lesions and the Child-Pugh score were identified as independent prognostic factors in the training cohort. The development of a 0-7-point prognostic score, named the Chiba HCC in intermediate-stage prognostic (CHIP) score, was based on the sum of three subscale scores (Child-Pugh score = 0, 1, 2, or 3, respectively, number of lesions = 0, 2, or 3, respectively, HCV-RNA positivity = 0 or 1, respectively). The generated scores were then differentiated into five groups (0-2 points, 3 points, 4 points, 5 points, and 6-7 points) by the median survival time (65.2, 29.2, 24.3, 13.1, and 8.4 months, respectively; p < 0.0001). These results were confirmed in the external validation cohort (p < 0.0001).
The CHIP score is easy-to-use and may assist in finding an appropriate treatment strategy for intermediate-stage HCC.</description><subject>Aged</subject><subject>Aspartate</subject><subject>Aspartate aminotransferase</subject><subject>C-reactive protein</subject><subject>Carcinoma, Hepatocellular - blood supply</subject><subject>Carcinoma, Hepatocellular - mortality</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Carcinoma, Hepatocellular - therapy</subject><subject>Care and treatment</subject><subject>Chemoembolization</subject><subject>Chemoembolization, Therapeutic</subject><subject>Creatinine</subject><subject>Datasets</subject><subject>Development and progression</subject><subject>Etiology</subject><subject>Female</subject><subject>Gastroenterology</subject><subject>Hepatitis C virus</subject><subject>Hepatocellular carcinoma</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Lesions</subject><subject>Liver</subject><subject>Liver cancer</subject><subject>Liver Neoplasms - blood supply</subject><subject>Liver Neoplasms - mortality</subject><subject>Liver Neoplasms - pathology</subject><subject>Liver Neoplasms - therapy</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Multivariate Analysis</subject><subject>Neoplasm Staging</subject><subject>Nephrology</subject><subject>Patients</subject><subject>Pretreatment</subject><subject>Prognosis</subject><subject>Proteins</subject><subject>Regression analysis</subject><subject>Regression models</subject><subject>Reproducibility of Results</subject><subject>Ribonucleic acid</subject><subject>RNA</subject><subject>Statistical analysis</subject><subject>Survival</subject><subject>Survival analysis</subject><subject>Tomography</subject><subject>Training</subject><subject>Tumors</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNk12L1DAUhoso7rr6D0QLgujFjEmapO2NMCx-DCws-HUbTtPTNkPbzCapX-B_N92ZXWZkLyQXDenzvsl5k5MkTylZ0iynbzZ2ciP0y60dcUkoE4zze8kpLTO2kIxk9w_mJ8kj7zeEiKyQ8mFywkRJS8LEafJnlW6dbUfrg9Gp19Zh2liXbiEYHINPf5jQpWYM6AasDQRc-AAtph1GxGrs-6kHl2pw2ox2gDQ4jFS9EwYHowcX1Qb6VHc4WBwq25vf0d-Oj5MHDfQen-y_Z8nX9---nH9cXFx-WJ-vLhZaliwsKkGFoFJLKGghcy5p3RDOG6zygjFouKxqjQzqUgsh67KSGRcMiCaAOQOdnSXPd77b3nq1T84rKnOZZTInZSTWO6K2sFFbZwZwv5QFo64XrGtVLMPoHlVFa8w0Clo1nNeiLAoudY2VkCRjJBfR6-1-t6mKoemYo4P-yPT4z2g61drvivN4jfl8mFd7A2evJvRBDcbPUcOIdro-d16UPGYT0Rf_oHdXt6daiAWYsbFxXz2bqhVnlBcxVRqp5R1UHDUORsdn1pi4fiR4fSSITMCfoYXJe7X-_On_2ctvx-zLA7ZD6EPnbT_NT8Yfg3wHame9d9jchkyJmrvkJg01d4nad0mUPTu8oFvRTVtkfwFmLw_z</recordid><startdate>20150428</startdate><enddate>20150428</enddate><creator>Ogasawara, Sadahisa</creator><creator>Chiba, Tetsuhiro</creator><creator>Ooka, Yoshihiko</creator><creator>Kanogawa, Naoya</creator><creator>Motoyama, Tenyu</creator><creator>Suzuki, Eiichiro</creator><creator>Tawada, Akinobu</creator><creator>Azemoto, Ryosaku</creator><creator>Shinozaki, Masami</creator><creator>Yoshikawa, Masaharu</creator><creator>Yokosuka, Osamu</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20150428</creationdate><title>A prognostic score for patients with intermediate-stage hepatocellular carcinoma treated with transarterial chemoembolization</title><author>Ogasawara, Sadahisa ; Chiba, Tetsuhiro ; Ooka, Yoshihiko ; Kanogawa, Naoya ; Motoyama, Tenyu ; Suzuki, Eiichiro ; Tawada, Akinobu ; Azemoto, Ryosaku ; Shinozaki, Masami ; Yoshikawa, Masaharu ; Yokosuka, Osamu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-b515516c6a81867461df044feb7822af46bdce2ad9c556d9b63452a0c0ae72ac3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Aged</topic><topic>Aspartate</topic><topic>Aspartate aminotransferase</topic><topic>C-reactive protein</topic><topic>Carcinoma, Hepatocellular - blood supply</topic><topic>Carcinoma, Hepatocellular - mortality</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Carcinoma, Hepatocellular - therapy</topic><topic>Care and treatment</topic><topic>Chemoembolization</topic><topic>Chemoembolization, Therapeutic</topic><topic>Creatinine</topic><topic>Datasets</topic><topic>Development and progression</topic><topic>Etiology</topic><topic>Female</topic><topic>Gastroenterology</topic><topic>Hepatitis C virus</topic><topic>Hepatocellular carcinoma</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Lesions</topic><topic>Liver</topic><topic>Liver cancer</topic><topic>Liver Neoplasms - blood supply</topic><topic>Liver Neoplasms - mortality</topic><topic>Liver Neoplasms - pathology</topic><topic>Liver Neoplasms - therapy</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Multivariate Analysis</topic><topic>Neoplasm Staging</topic><topic>Nephrology</topic><topic>Patients</topic><topic>Pretreatment</topic><topic>Prognosis</topic><topic>Proteins</topic><topic>Regression analysis</topic><topic>Regression models</topic><topic>Reproducibility of Results</topic><topic>Ribonucleic acid</topic><topic>RNA</topic><topic>Statistical analysis</topic><topic>Survival</topic><topic>Survival analysis</topic><topic>Tomography</topic><topic>Training</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ogasawara, Sadahisa</creatorcontrib><creatorcontrib>Chiba, Tetsuhiro</creatorcontrib><creatorcontrib>Ooka, Yoshihiko</creatorcontrib><creatorcontrib>Kanogawa, Naoya</creatorcontrib><creatorcontrib>Motoyama, Tenyu</creatorcontrib><creatorcontrib>Suzuki, Eiichiro</creatorcontrib><creatorcontrib>Tawada, Akinobu</creatorcontrib><creatorcontrib>Azemoto, Ryosaku</creatorcontrib><creatorcontrib>Shinozaki, Masami</creatorcontrib><creatorcontrib>Yoshikawa, Masaharu</creatorcontrib><creatorcontrib>Yokosuka, Osamu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ogasawara, Sadahisa</au><au>Chiba, Tetsuhiro</au><au>Ooka, Yoshihiko</au><au>Kanogawa, Naoya</au><au>Motoyama, Tenyu</au><au>Suzuki, Eiichiro</au><au>Tawada, Akinobu</au><au>Azemoto, Ryosaku</au><au>Shinozaki, Masami</au><au>Yoshikawa, Masaharu</au><au>Yokosuka, Osamu</au><au>Huang, Yi-Hsiang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A prognostic score for patients with intermediate-stage hepatocellular carcinoma treated with transarterial chemoembolization</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2015-04-28</date><risdate>2015</risdate><volume>10</volume><issue>4</issue><spage>e0125244</spage><epage>e0125244</epage><pages>e0125244-e0125244</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Intermediate-stage hepatocellular carcinoma (HCC), defined according to the Barcelona Clinic Liver Cancer (BCLC) staging system, is a heterogeneous condition with variable clinical benefits from transarterial chemoembolization (TACE). This study aimed to develop a simple validated prognostic score based on the predictive factors for survival in patients with intermediate-stage HCC treated with TACE.
Three-hundred and fifty patients with intermediate-stage HCC undergoing initial TACE at Chiba University Hospital (training cohort; n = 187) and two affiliated hospitals (validation cohort; n = 163) were included. Following variables were entered into univariate and multivariate Cox regression models to develop a points-based clinical scoring system: gender, age, etiology, pretreatment, Child-Pugh score, aspartate aminotransferase, creatinine, C-reactive protein, alfa-fetoprotein, size of the largest lesion, and number and location of lesions.
The number of lesions and the Child-Pugh score were identified as independent prognostic factors in the training cohort. The development of a 0-7-point prognostic score, named the Chiba HCC in intermediate-stage prognostic (CHIP) score, was based on the sum of three subscale scores (Child-Pugh score = 0, 1, 2, or 3, respectively, number of lesions = 0, 2, or 3, respectively, HCV-RNA positivity = 0 or 1, respectively). The generated scores were then differentiated into five groups (0-2 points, 3 points, 4 points, 5 points, and 6-7 points) by the median survival time (65.2, 29.2, 24.3, 13.1, and 8.4 months, respectively; p < 0.0001). These results were confirmed in the external validation cohort (p < 0.0001).
The CHIP score is easy-to-use and may assist in finding an appropriate treatment strategy for intermediate-stage HCC.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>25919025</pmid><doi>10.1371/journal.pone.0125244</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2015-04, Vol.10 (4), p.e0125244-e0125244 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_1676336709 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Public Library of Science (PLoS); PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Aged Aspartate Aspartate aminotransferase C-reactive protein Carcinoma, Hepatocellular - blood supply Carcinoma, Hepatocellular - mortality Carcinoma, Hepatocellular - pathology Carcinoma, Hepatocellular - therapy Care and treatment Chemoembolization Chemoembolization, Therapeutic Creatinine Datasets Development and progression Etiology Female Gastroenterology Hepatitis C virus Hepatocellular carcinoma Hospitals Humans Kaplan-Meier Estimate Lesions Liver Liver cancer Liver Neoplasms - blood supply Liver Neoplasms - mortality Liver Neoplasms - pathology Liver Neoplasms - therapy Male Medical prognosis Medicine Multivariate Analysis Neoplasm Staging Nephrology Patients Pretreatment Prognosis Proteins Regression analysis Regression models Reproducibility of Results Ribonucleic acid RNA Statistical analysis Survival Survival analysis Tomography Training Tumors |
| title | A prognostic score for patients with intermediate-stage hepatocellular carcinoma treated with transarterial chemoembolization |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T00%3A48%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20prognostic%20score%20for%20patients%20with%20intermediate-stage%20hepatocellular%20carcinoma%20treated%20with%20transarterial%20chemoembolization&rft.jtitle=PloS%20one&rft.au=Ogasawara,%20Sadahisa&rft.date=2015-04-28&rft.volume=10&rft.issue=4&rft.spage=e0125244&rft.epage=e0125244&rft.pages=e0125244-e0125244&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0125244&rft_dat=%3Cgale_plos_%3EA421488671%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1676336709&rft_id=info:pmid/25919025&rft_galeid=A421488671&rft_doaj_id=oai_doaj_org_article_b1de3ce51bf44d598846cdeb56032075&rfr_iscdi=true |